Dale New Material mass-produces foldable screen back glass for a leading consumer electronics company; robot tungsten wire tendon ropes may generate sizable revenue next year

Article body

On October 30, several listed companies released announcements of investor relations activity records, disclosing the content of their business exchanges with institutions, which revealed many developments and highlights in the companies' business layouts.

Dailer New Materials: Huizhou Company's Phase I project is running at full capacity, and is mass-producing foldable-screen backplane glass for a major customer

Dailer New Materials recently received research visits from institutional investors including Guotai Haitong, Guotai Fund, and ICBC Credit Suisse.

During the exchange, Dailer New Materials stated that, with the photovoltaic industry under pressure, the company has focused on strengthening the promotion of diamond wire in non-photovoltaic fields, and the revenue share of non-photovoltaic products has exceeded 40%.

It is reported that Huizhou Dailer mainly provides glass backplane cutting support for an international consumer electronics leader. The Phase I capacity has been fully completed and is running at full capacity, and the first product in mass production is the foldable-screen backplane glass newly launched by the customer. "In the next two years, the mass production of new model products will gradually increase, and future revenue levels will grow significantly on the existing basis."

Regarding the third-quarter loss, the company stated that there are two main reasons: first, the price of tungsten raw materials fell sharply, and tungsten material recycling suffered a one-sided value loss, which, combined with risk control, led to a decline in diamond wire sales;

second, the launch pace of customers' new products had an impact. In the third quarter, Huizhou Company's new product processing business was basically in a preparatory state and only reached full capacity at the end of September, so the release of related business revenue was delayed compared with the plan.

The company's robotic tungsten wire tendon rope products are currently continuing validation work with relevant mainstream domestic manufacturers, and are expected to generate sizable revenue next year.

Pharmaron: In the first three quarters, new orders in the CDMO segment increased by more than 40% year on year

Pharmaron recently held a conference call to exchange online with more than 300 institutions, including Morgan Stanley, Galaxy Securities, and Goldman Sachs, on the company's latest performance and business progress.

During the exchange, Pharmaron stated that in the third quarter, the company's revenue and profit achieved relatively rapid growth both year on year and quarter on quarter. Along with the growth in revenue scale, the company's Non-IFRS adjusted net profit margin attributable to shareholders improved quarter on quarter.

In terms of new orders, in the first three quarters, the company's new orders increased by more than 30% year on year, continuing the strong trend from the first half of the year.

Among them, new orders in the CDMO segment increased by more than 40% year on year, continuing the strong growth trend; new orders in clinical services increased by more than 25% year on year, maintaining a rapid growth trend.

Regarding MNC customers, in the first three quarters, the company's revenue from the world's top 20 pharmaceutical companies grew by 52.5%, accounting for 23% of overall revenue. In the third quarter, late-stage projects of some European pharmaceutical companies achieved large deliveries, directly driving faster revenue growth from MNC customers and European customers, contributed by the small-molecule CDMO business.

The company also introduced that in the third quarter, its API production workshop in Ningbo once again passed an FDA on-site inspection, providing strong support for the company to continue serving commercial innovative drug production in the U.S. and global markets.

The company's CRDMO pipeline serves nearly a thousand R&D projects each year. With the continued advancement of the small-molecule CDMO pipeline, demand for mid-to-late clinical and commercial production projects is expected to continue to maintain strong growth.

(Source: East Money Research Center) Middle of the body Embedded advertisement